Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use

Abraham, J. M. (2010) · Brill | Nijhoff eBooks · doi:10.1163/ej.9789004163300.i-1081.897 · Cited by 2,612 · see citing works

Identification of a Primary Target of Thalidomide Teratogenicity

Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136 · see citing works

Frequent pathway mutations of splicing machinery in myelodysplasia

Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029 · see citing works

Initial genome sequencing and analysis of multiple myeloma

Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C. L., Schinzel, A. C., Harview, C. L., Brunet, J.-P., Ahmann, G. J., Adli, M., et al. (2011) · Nature · doi:10.1038/nature09837 · Cited by 1,422 · see citing works

Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts

Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222 · see citing works

SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia

Wang, L., Lawrence, M. S., Wan, Y., Stojanov, P., Sougnez, C. L., Stevenson, K. E., Werner, L. L., Sivachenko, A., DeLuca, D. S., Zhang, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109016 · Cited by 1,081 · see citing works

Ensembl 2012

Flicek, P., Amode, M. R., Barrell, D. G., Beal, K. M., Brent, S., Carvalho‐Silva, D., Clapham, P., Coates, G. M. P., Fairley, S., Fitzgerald, S. F., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr991 · Cited by 818 · see citing works

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814 · see citing works

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Miguel, J. F. S., Weisel, K. C., Moreau, P., Lacy, M. Q., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 800 · see citing works

International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH).

Baber, N. S. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb05705.x · Cited by 762 · see citing works

The Ubiquitin Ligase Activity in the DDB2 and CSA Complexes Is Differentially Regulated by the COP9 Signalosome in Response to DNA Damage

Groisman, R., Polanowska, J., Kuraoka, I., Sawada, J.-I., Saijo, M., Drapkin, R., Kisselev, A. F., Tanaka, K., & Nakatani, Y. (2003) · Cell · doi:10.1016/s0092-8674(03)00316-7 · Cited by 739 · see citing works

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607 · see citing works

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

Rossi, D., Bruscaggin, A., Spina, V., Rasi, S., Khiabanian, H., Messina, M., Fangazio, M., Vaisitti, T., Monti, S. M., Chiaretti, S., et al. (2011) · Blood · doi:10.1182/blood-2011-08-373159 · Cited by 372 · see citing works

High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance

Broyl, A., Kuiper, R., van Duin, M., van der Holt, B., el Jarari, L., Bertsch, U., Zweegman, S., Buijs, A., Hose, D., Lokhorst, H. M., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438101 · Cited by 131 · see citing works

Alternatively spliced glucocorticoid receptor messenger RNAs in glucocorticoid-resistant human multiple myeloma cells.

Moalli, P., Pillay, S., Krett, N. L., & Rosen, S. T. (1993) · PubMed · Cited by 128 · see citing works

High expression of cereblon (<i><scp>CRBN</scp></i>) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone

Heintel, D., Rocci, A., Ludwig, H., Bolomsky, A., Caltagirone, S., Schreder, M., Pfeifer, S., Gisslinger, H., Zojer, N., Jäger, U., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12338 · Cited by 128 · see citing works

SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients

Lasho, T. L., Finke, C. M., Hanson, C. A., Jimma, T., Knudson, R. A., Ketterling, R. P., Pardanani, A. D., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.320 · Cited by 117 · see citing works

Small-Molecule Inhibition of HIV pre-mRNA Splicing as a Novel Antiretroviral Therapy to Overcome Drug Resistance

Bakkour, N., Lin, Y., Maire, S., Ayadi, L., Mahuteau‐Betzer, F., Nguyen, C. H., Mettling, C., Portalès, P., Grierson, D. S., Chabot, B., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030159 · Cited by 93 · see citing works

Genome-wide association study of antibody response to smallpox vaccine

Ovsyannikova, I. G., Kennedy, R. B., O’Byrne, M. M., Jacobson, R. M., Pankratz, V. S., & Poland, G. A. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.055 · Cited by 82 · see citing works

BCR-ABLalternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations

Lee, T., Ma, W., Zhang, X., Giles, F. J., Cortes, J. E., Kantarjian, H. M., & Albitar, M. X. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0482 · Cited by 65 · see citing works

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy

Thakurta, A., Gandhi, A. K., Waldman, M. F., Bjorklund, C., Ning, Y., Mendy, D., Schafer, P., Lopez-Girona, A., Lentzsch, S., Schey, S. A., et al. (2014) · Leukemia · doi:10.1038/leu.2013.315 · Cited by 56 · see citing works

High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide

Klimowicz, A. C., Neri, P. E., Belch, A., Dean, M. L., Ren, L., Gratton, K., Slabý, J., Johnson, J., Duggan, P. R., Stewart, D. A., et al. (2012) · Blood · doi:10.1182/blood.v120.21.931.931 · Cited by 15 · see citing works

Use of alternate splicing to identify subgroups in uniformly treated newly-diagnosed myeloma

Munshi, N. C., Li, C., Minvielle, S., Moreau, P., Amin, S. B., Magrangeas, M., Anderson, K. C., & Avet‐Loiseau, H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8602 · Cited by 1 · see citing works

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs

Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural &amp; Molecular Biology · doi:10.1038/nsmb.2874 · Cited by 531 · see citing works

Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome

Donovan, K. A., An, J., Nowak, R. P., Yuan, J. C., Fink, E. C., Berry, B. C., Ebert, B. L., & Fischer, E. S. (2018) · eLife · doi:10.7554/elife.38430 · Cited by 509 · see citing works

SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate

Matyskiela, M. E., Couto, S., Zheng, X., Lu, G., Hui, J., Stamp, K., Drew, C., Ren, Y., Wang, M., Carpenter, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0129-x · Cited by 338 · see citing works

Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4

Bjorklund, C. C., Lu, L., Kang, J., Hagner, P. R., Havens, C. G., Amatangelo, M., Wang, M., Ren, Y., Couto, S., Breider, M., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.66 · Cited by 221 · see citing works

Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity

Eichner, R., Heider, M., Fernández-Sáiz, V., van Bebber, F., Garz, A.-K., Lemeer, S., Rudelius, M., Targosz, B.-S., Jacobs, L., Knorn, A.-M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4128 · Cited by 183 · see citing works

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Gooding, S., Ansari-Pour, N., Towfic, F., Ortiz Estévez, M., Chamberlain, P. P., Tsai, K.-T., Flynt, E., Hirst, M., Rozelle, D., Dhiman, P., et al. (2021) · Blood · doi:10.1182/blood.2020007081 · Cited by 172 · see citing works

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when

Caers, J., Garderet, L., Kortüm, K. M., O'Dwyer, M. E., van de Donk, N. W. C. J., Binder, M., Dold, S. M., Gay, F., Corre, J., Beguin, Y. P., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.189159 · Cited by 153 · see citing works

Prognostic and predictive biomarker developments in multiple myeloma

Wallington-Beddoe, C. T., & Mynott, R. L. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01162-7 · Cited by 141 · see citing works

Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide

Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137 · see citing works

Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets

Sehgal, K., Das, R., Zhang, L., Verma, R., Deng, Y., Kocoglu, M. H., Vasquez, J. C., Koduru, S. V., Ren, Y., Wang, M., et al. (2015) · Blood · doi:10.1182/blood-2014-11-611426 · Cited by 134 · see citing works

Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins

Shirasaki, R., Matthews, G. M., Gandolfi, S., de Matos Simoes, R., Buckley, D. L., Raja Vora, J., Sievers, Q. L., Brüggenthies, J. B., Dashevsky, O., Poarch, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108532 · Cited by 123 · see citing works

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance

Paiva, B., Corchete, L. A., Vídriales, M., Puig, N., Maiso, P., Rodríguez, I., Alignani, D., Burgos, L., Sánchez, M.-L., Bárcena, P., et al. (2016) · Blood · doi:10.1182/blood-2015-08-665679 · Cited by 104 · see citing works

In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

Ocio, E. M., Fernández‐Lázaro, D., San‐Segundo, L., López‐Corral, L., Corchete, L. A., Gutierrez, N. C., Garayoa, M., Paíno, T., García-Gómez, A., Delgado, M., et al. (2014) · Leukemia · doi:10.1038/leu.2014.238 · Cited by 90 · see citing works

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner

Dimopoulos, K., Helbo, A. S., Munch‐Petersen, H. F., Sjø, L. D., Christensen, J. F., Kristensen, L. S., Asmar, F., Hermansen, E., O'Connel, C., Gimsing, P., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12157 · Cited by 88 · see citing works

p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates

Nguyen, T. V., Li, J., Lu, C.-C. (., Mamrosh, J. L., Lu, G., Cathers, B. E., & Deshaies, R. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700949114 · Cited by 85 · see citing works

Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption

Mondala, P. K., Vora, A. A., Zhou, T., Lazzari, E., Ladel, L., Luo, X., Kim, Y., Costello, C. L., MacLeod, A. R., Jamieson, C. H. M., et al. (2021) · Cell stem cell · doi:10.1016/j.stem.2020.12.017 · Cited by 68 · see citing works

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients

Franssen, L. E., Nijhof, I. S., Couto, S., Levin, M.-D., Bos, G. M. J., Broijl, A., Klein, S. K., Ren, Y., Wang, M., Koene, H. R., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.186601 · Cited by 66 · see citing works

Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs

Sperling, A. S., Burgess, M. W., Keshishian, H., Gasser, J. A., Bhatt, S., Jan, M., Slabicki, M. M., Sellar, R. S., Fink, E. C., Miller, P. G., et al. (2019) · Blood · doi:10.1182/blood.2019000789 · Cited by 65 · see citing works

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma

Huang, S.-Y., Lin, C.-W., Lin, H.-H., Yao, M., Tang, J.-L., Wu, S.-J., Chen, Y.-C., Lu, H.-Y., Hou, H.-A., Chen, C.-Y., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2063-7 · Cited by 62 · see citing works

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy

Thakurta, A., Gandhi, A. K., Waldman, M. F., Bjorklund, C., Ning, Y., Mendy, D., Schafer, P., Lopez-Girona, A., Lentzsch, S., Schey, S. A., et al. (2014) · Leukemia · doi:10.1038/leu.2013.315 · Cited by 56 · see citing works

Targeting cereblon in hematologic malignancies

Fuchs, O. (2023) · Blood Reviews · doi:10.1016/j.blre.2022.100994 · Cited by 55 · see citing works

A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function

Liu, Y., Huang, X., He, X., Zhou, Y., Jiang, X., Chen‐Kiang, S., Jaffrey, S. R., & Xu, G. (2015) · The FASEB Journal · doi:10.1096/fj.15-274050 · Cited by 55 · see citing works

Cereblon in health and disease

Kim, H. K., Ko, T. H., Nyamaa, B., Lee, S. R., Kim, N., Ko, K. S., Rhee, B. D., Park, C., Nilius, B., & Han, J. (2016) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-016-1854-1 · Cited by 55 · see citing works

Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon

Akuffo, A. A., Alontaga, A. Y., Metcalf, R. S., Beatty, M. S., Becker, A., McDaniel, J. M., Hesterberg, R. S., Goodheart, W. E., Gunawan, S., Ayaz, M., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816868 · Cited by 55 · see citing works

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling

Díaz, T., Rodríguez, V., Lozano, E., Mena, M.-P., Calderón, M., Rosiñol, L., Martı́nez, A., Tovar, N., Pérez‐Galán, P., Bladé, J., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.164632 · Cited by 52 · see citing works

USP15 antagonizes CRL4 CRBN -mediated ubiquitylation of glutamine synthetase and neosubstrates

Nguyen, T. V. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111391118 · Cited by 49 · see citing works

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)

Krönke, J., Kuchenbauer, F., Kull, M., Teleanu, V, Bullinger, L., Bunjes, D., Greiner, A., Kolmus, S., Köpff, S., Schreder, M., et al. (2017) · Leukemia · doi:10.1038/leu.2016.384 · Cited by 46 · see citing works

Multiple myeloma cells’ capacity to decompose H2O2 determines lenalidomide sensitivity

Sebastian, S., Zhu, Y. X., Braggio, E., Shi, C.-X., Panchabhai, S. C., Wier, S. A. V., Ahmann, G. J., Chesi, M., Bergsagel, P. L., Stewart, A. K., et al. (2016) · Blood · doi:10.1182/blood-2016-09-738872 · Cited by 45 · see citing works

Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?

Cieślak, M., & Słowianek, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030812 · Cited by 41 · see citing works

Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2

Shrestha, P., Davis, D. A., Jaeger, H. K., Stream, A., Aisabor, A. I., & Yarchoan, R. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009091 · Cited by 39 · see citing works

Structure-guided bifunctional molecules hit a DEUBAD-lacking hRpn13 species upregulated in multiple myeloma

Lu, X., Sabbasani, V. R., Amponsa, V. O., Evans, C. N., King, J. C., Tarasov, S. G., Dyba, M., Das, S., Chan, K. C., Schwieters, C. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27570-4 · Cited by 35 · see citing works

Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities

Roy, A. L., Prébet, T., Castellano, R., Goubard, A., Riccardi, F., Fauriat, C., Granjeaud, S., Benyamine, A., Castanier, C., Orlanducci, F., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00977 · Cited by 35 · see citing works

Understanding the multiple biological aspects leading to myeloma

Boyle, E. M., Davies, F. E., Leleu, X. P., & Morgan, G. J. (2014) · Haematologica · doi:10.3324/haematol.2013.097907 · Cited by 32 · see citing works

High level of full‐length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

Jonasova, A., Bokorova, R., Polak, J., Vostry, M., Kostecka, A., Hajkova, H., Neuwirtova, R., Siskova, M., Sponerova, D., Cermak, J., et al. (2015) · European Journal of Haematology · doi:10.1111/ejh.12457 · Cited by 31 · see citing works

Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma

Dimopoulos, K., Munch‐Petersen, H. F., Eskelund, C. W., Sjø, L. D., Ralfkiaer, E. M., Gimsing, P., & Grønbæk, K. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1466290 · Cited by 29 · see citing works

Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs

Beedie, S., Huang, P. A., Harris, E. M., Strope, J. D., Mahony, C. B., Chau, C. H., Vargesson, N., & Figg, W. D. (2020) · The FASEB Journal · doi:10.1096/fj.201903060rr · Cited by 28 · see citing works

Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma

Misiewicz-Krzemińska, I., Ramón, C. D., Corchete, L. A., Krzemiński, P., Rojas, E. A., Isidro, I. M., García‐Sánz, R., Martínez‐López, J., Oriol, A., Bladé, J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002711 · Cited by 27 · see citing works

Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives

Kulig, P., Milczarek, S., Bakinowska, E., Szalewska, L., Baumert, B., & Machaliński, B. (2023) · Cancers · doi:10.3390/cancers15030963 · Cited by 26 · see citing works

Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs

Fuchs, O. (2018) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x18666180522073855 · Cited by 26 · see citing works

BSG and MCT1 Genetic Variants Influence Survival in Multiple Myeloma Patients

Łacina, P., Butrym, A. K., Mazur, G. J., & Bogunia‐Kubik, K. (2018) · Genes · doi:10.3390/genes9050226 · Cited by 24 · see citing works

CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers

Kwiatkowski, N., Liang, T., Sha, Z., Collier, P. N., Yang, A., Sathappa, M., Paul, A., Su, L., Zheng, X., Aversa, R., et al. (2025) · Cell Chemical Biology · doi:10.1016/j.chembiol.2025.03.006 · Cited by 23 · see citing works

Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs

Vicente, A. T. S., Moura, S. P. S. P., & Salvador, J. A. R. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01598-9 · Cited by 23 · see citing works

Pomalidomide for the treatment of relapsed–refractory multiple myeloma: a review of biological and clinical data

Offidani, M., Corvatta, L., Caraffa, P., Leoni, P., Pautasso, C., Larocca, A., & Palumbo, A. P. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.906904 · Cited by 22 · see citing works

Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment

Butrym, A. K., Rybka, J., Łacina, P., Gębura, K., Frontkiewicz, D., Bogunia‐Kubik, K., & Mazur, G. J. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.10.007 · Cited by 21 · see citing works

Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib‐based treatment regimens

Dytfeld, D., Rosebeck, S., Kandarpa, M., Mayampurath, A. M., Mellacheruvu, D., Alonge, M. M., Ngoka, L. C. M., Jasielec, J. K., Richardson, P. G. G., Volchenboum, S. L., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13394 · Cited by 18 · see citing works

Baicalein Inhibits Proliferation of Myeloma U266 Cells by Downregulating IKZF1 and IKZF3

Liu, X., Li, H., Zhang, Q., Zeng, X., & Liu, S.-Q. (2018) · Medical Science Monitor · doi:10.12659/msm.907058 · Cited by 18 · see citing works

The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma

Sellin, M., Berg, S. A., Hagen, P. A., & Zhang, J. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101448 · Cited by 17 · see citing works

A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma

Oekelen, O. V., Parekh, S. S., Cho, H. J., Vishnuvardhan, N., Madduri, D., Richter, J. R., Ip, C., Lau, K., Florendo, E., Mancia, I. S., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1805111 · Cited by 16 · see citing works

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility

Misiewicz-Krzemińska, I., Corchete, L. A., Rojas, E. A., Martínez‐López, J., García‐Sánz, R., Oriol, A., Bladé, J., Lahuerta, J. J., Miguel, J. F. S., Mateos, M., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.181628 · Cited by 16 · see citing works

A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples

Ren, Y., Wang, M., Couto, S. S., Hansel, D. E., Miller, K., Lopez‐Girona, A., Bjorklund, C. C., Gandhi, A. K., Thakurta, A., Chopra, R., et al. (2015) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000246 · Cited by 16 · see citing works

IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide‐dexamethasone therapy in multiple myeloma

Bolomsky, A., Hübl, W., Spada, S., Müldür, E., Schlangen, K., Heintel, D., Rocci, A., Weißmann, A., Fritz, V., Willheim, M., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24634 · Cited by 15 · see citing works

Cereblon: promise and challenges for combating human diseases

Kim, H. K., Seol, J. E., Ahn, S. W., Jeon, S., Park, C., & Han, J. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-021-02624-0 · Cited by 14 · see citing works

Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors

Maffei, R., Colaci, E., Fiorcari, S., Martinelli, S., Potenza, L., Luppi, M., & Marasca, R. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.09.003 · Cited by 13 · see citing works

A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma

Kim, G. W., Yoo, J. H., Won, H.-R., Yeon, S.-K., Lee, S. W., Lee, D. H., Jeon, Y. H., & Kwon, S. H. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106398 · Cited by 12 · see citing works

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma

Chen, L., & Gooding, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1038329 · Cited by 12 · see citing works

Targeting plasma cells: are we any closer to a panacea for diseases of antibody‐secreting cells?

Low, M. S. Y., Infantino, S., Grigoriadis, G., & Tarlinton, D. M. (2016) · Immunological Reviews · doi:10.1111/imr.12388 · Cited by 12 · see citing works

Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B‐cell lymphoma of the mucosa‐associated lymphoid tissue (MALT lymphoma)

Kiesewetter, B., Simonitsch‐Klupp, I., Kornauth, C., Dolak, W., Lukas, J., Mayerhoefer, M. E., & Raderer, M. (2017) · Hematological Oncology · doi:10.1002/hon.2472 · Cited by 12 · see citing works

Caspase-8 Regulates the Antimyeloma Activity of Bortezomib and Lenalidomide

Zhou, L., Huang, X., Niesvizky, R., Pu, Z., & Xu, G. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000818 · Cited by 12 · see citing works

Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS

Qian, X., Dimopoulos, M. A., Amatangelo, M. D., Bjorklund, C. C., Towfic, F., Flynt, E., Weisel, K. C., Ocio, E. M., Yu, X., Peluso, T., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1485915 · Cited by 12 · see citing works

Modulation of cereblon levels by anti-myeloma agents

Dı́az-Rodrı́guez, E., & Pandiella, A. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1037752 · Cited by 11 · see citing works

Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium

Iskierka‐Jazdzewska, E., Canzian, F., Stępień, A., Martino, A., Campa, D., Stein, A., Krawczyk‐Kuliś, M., Rybicka‐Ramos, M., Kyrcz‐Krzemień, S., Butrym, A. K., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1689391 · Cited by 10 · see citing works

Mechanism of immunomodulatory drug resistance and novel therapeutic strategies in multiple myeloma

Zuo, X., & Liu, D. (2022) · Hematology · doi:10.1080/16078454.2022.2124694 · Cited by 9 · see citing works

Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function

Zhou, L., Yu, W.-J., Jayabalan, D. S., Niesvizky, R., Jaffrey, S. R., Huang, X., & Xu, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.605989 · Cited by 9 · see citing works

Lys-63-specific deubiquitinase BRCC36 enhances the sensitivity of multiple myeloma cells to lenalidomide by inhibiting lysosomal degradation of cereblon

Wang, B., Li, M., Cao, D., Sun, Q., Yu, W.-J., Ma, J., Ren, H., Xu, G., & Zhou, L. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05390-1 · Cited by 8 · see citing works

Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide

Maffei, R., Fiorcari, S., Martinelli, S., Benatti, S., Bulgarelli, J., Rizzotto, L., Debbia, G., Santachiara, R., Rigolin, G. M., Forconi, F., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1339872 · Cited by 7 · see citing works

Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low‐Dose Dexamethasone

Li, Y., Kassir, N., Wang, X., Palmisano, M., & Zhou, S. Y. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1602 · Cited by 7 · see citing works

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide

Huang, P. A., Beedie, S., Chau, C. H., Venzon, D. J., Gere, S., Kazandjian, D. G., Korde, N., Mailankody, S., Landgren, O., & Figg, W. D. (2019) · Scientific Reports · doi:10.1038/s41598-019-51446-9 · Cited by 7 · see citing works

The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients

Barankiewicz, J., Szumera-Ciećkiewicz, A., Salomon-Perzyński, A., Wieszczy, P., Malenda, A., Garbicz, F., Prochorec-Sobieszek, M., Misiewicz-Krzemińska, I., Juszczyński, P., & Lech-Marańda, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122683 · Cited by 7 · see citing works

Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways

Karagoz, K., Stokes, M. P., Ortiz-Estévez, M., Towfic, F., Flynt, E., Gooding, S., Pierceall, W. E., & Thakurta, A. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.831779 · Cited by 6 · see citing works

Pan-cancer analysis reveals the prognostic and immunologic roles of cereblon and its significance for PROTAC design

Zhang, S.-H., Zeng, N., Sun, J., Liu, C., Xu, J., Xu, M., An, Y., Zhong, X., Ma, S., He, H., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16644 · Cited by 6 · see citing works

Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma

Chang, X.-B., Xu, Q., Hou, Y., Li, C., Xu, Y., & Stewart, A. K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091999 · Cited by 6 · see citing works

The histone demethylase KDM5C enhances the sensitivity of acute myeloid leukemia cells to lenalidomide by stabilizing cereblon

Zou, L., Cao, D., Sun, Q. P., Yu, W.-J., Li, B.-Z., Xu, G., & Zhou, L. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00697-8 · Cited by 5 · see citing works

Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy

Kuroda, J., Kobayashi, T., & Taniwaki, M. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1044249 · Cited by 5 · see citing works

Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent

Mondello, P., Pitini, V. V., Barresi, V., Brea, E. J., Mirto, C. D., Arrigo, C., Cuzzocrea, S., & Mian, M. (2015) · Experimental Hematology and Oncology · doi:10.1186/s40164-015-0030-1 · Cited by 5 · see citing works

Immunomodulatory drugs and their therapeutic effect in hematological malignancies through cereblon

Fuchs, O. (2017) · Hematology & Medical Oncology · doi:10.15761/hmo.1000129 · Cited by 5 · see citing works

High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients

Borsi, E., Mazzocchetti, G., Dico, A. F., Vigliotta, I., Martello, M., Poletti, A., Solli, V., Armuzzi, S., Taurisano, B., Kanapari, A., et al. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01205-y · Cited by 5 · see citing works

Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications

Knoll, N., Neamati, N., & Üren, A. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00730 · Cited by 4 · see citing works

A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Chari, A., Cho, H. J., Parekh, S. S., Lau, K., Morgan, G., Catamero, D., Cortes, M., Curtis, M., Escalon, J., Florendo, E., et al. (2016) · Blood · doi:10.1182/blood.v128.22.4520.4520 · Cited by 4 · see citing works

The treatment of multiple myeloma in an era of precision medicine

Kint, N., Vlayen, S., & Delforge, M. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1606672 · Cited by 4 · see citing works

[Advances on immunomodulatory drugs against multiple myeloma].

Wang, S., & Jin, F. (2016) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2016.03.021 · Cited by 3 · see citing works

Cereblon – a New Target of Therapy in the Treatment of Multiple Myeloma

Staňková, M., Bešše, L., Sedlaříková, L., Vrábel, D., Hájek, R., & Ševčı́ková, S. (2014) · Klinicka onkologie · doi:10.14735/amko2014326 · Cited by 2 · see citing works

Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients

Lee, B., Kang, K., Jeon, M. J., Yu, E. S., Kim, D. S., Lee, S. R., Sung, H. J., Park, Y., Choi, C. W., & Kim, B. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.687361 · Cited by 2 · see citing works

Novel mechanisms of action for immunomodulatory drugs (IMiDs) against multiple myeloma: from a tragedy to a therapy

Dai, Y., & Jin, F. (2016) · International Journal of Hematology and Therapy · doi:10.15436/2381-1404.15.008 · Cited by 2 · see citing works

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)

Kalff, A., Khong, T. T., Ramachandran, M., Walker, P., Schwarer, A. P., Roberts, A. W., Campbell, P. J., Filshie, R., Norton, S., Reynolds, J., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1948030 · Cited by 2 · see citing works

Application of HIV-1 viral protein R-derived-peptides as new E3 ligase-binding components of BRD4 degraders

Tsuji, K., Huang, X., Miyamoto, M., Sukegawa, S., Yokoo, H., Takeuchi, H., Demizu, Y., & Tamamura, H. (2025) · RSC Chemical Biology · doi:10.1039/d5cb00125k · Cited by 1 · see citing works

Tailoring treatment in myeloma: are there clues from biology?

Zojer, N., & Ludwig, H. (2015) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-015-0207-7 · Cited by 1 · see citing works

Toward optimizing pomalidomide therapy in MM patients

Podar, K. (2015) · Blood · doi:10.1182/blood-2015-05-641746 · Cited by 1 · see citing works

Pomalidomide for the treatment of relapsed and refractory multiple myeloma

Guidetti, A., Prada, C. P., Laubach, J. P., Varga, C., Maglio, M. E., McKenney, M., Doss, D. S., Schlossman, R. L., Mitsiades, C. S., Hideshima, T., et al. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.953480 · Cited by 1 · see citing works

History of IMiDs and Protein Degradation as a Pharmacological Modality

Yamamoto, J., Asatsuma‐Okumura, T., Ito, T., Yamaguchi, Y., & Handa, H. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch8 · Cited by 1 · see citing works

Tumour Survival Signals and Epigenetic Gene Silencing in Multiple Myeloma : Implications for Biology and Therapy

Fristedt, C. (2015)

Zeroing in on cereblon

Heaney, M. L. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12525

Cereblon as a Predictive Biomarker for Imid Therapy Sensitivity

Gouri, A. (2014) · Journal of Hematology & Thromboembolic Diseases · doi:10.4172/2329-8790.1000e112

Cereblon and Its Role in the Treatment of Multiple Myeloma by Lenalidomide or Pomalidomide

Fuchs, O., Bokorová, R., Vostrý, M., Kostečka, A., & Poläk, J. (2014) · doi:10.12691/ijhd-1-1a-3

Myelodysplastic Disorders, 5q-Syndrome

Al‐Anazi, K. A. (2016) · InTech eBooks · doi:10.5772/64202

IMiD-induced gene expression profiling predicts multiple myeloma prognosis

Sebastian, S. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30153-9

Katenin-β és glutathion-S-transzferáz P1 génpolimorfizmusok vizsgálata myeloma multiplexben

Pál, I., Illés, Á., Nagy, B., Szilágyi, B., & Váróczy, L. (2018) · Hematológia–Transzfuziológia · doi:10.1556/2068.2018.51.2.5

The Impact of Beta-Catenin and glutathione-S-transferase Gene Polymorphisms on the Treatment Results and Survival of Multiple Myeloma Patients

Pál, I., Szilágyi, B., Nagy, B., Pál, T., Hodosi, K., Illés, Á., & Váróczy, L. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00747-5

[Progress in clonal evolution of multiple myeloma].

Wang, Y., An, G., & Qiu, L. (2021) · Europe PMC (PubMed Central) · doi:10.3760/cma.j.issn.0253-2727.2021.07.017

Serum cereblon level in Egyptian patients with multiple myeloma post autologous stem cell transplantation

Mostafa, N. N., El-Ghammaz, A. M. S., Abulmaged, D. F. A.-G. M., & Abdalla, N. E.-H. H. (2024) · The Egyptian Journal of Haematology · doi:10.4103/ejh.ejh_62_23

Cereblon upregulation overcomes thalidomide resistance in multiple myeloma through mitochondrial functional reprogramming

Marquez, J. C., Park, N., Choi, J. H., Garcia, M. V. F., Flores, J., Nyamaa, B., Seol, J. E., Kim, H. K., Shin, M., Park, S. G., et al. (2025) · BMB Reports · doi:10.5483/bmbrep.2024-0130

Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma

Dimopoulos, K., Munch‐Petersen, H. F., Eskelund, C. W., Sjø, L. D., Ralfkiaer, E. M., Gimsing, P., & Grønbæk, K. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1466290 · Cited by 29 · see citing works

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma

Huang, S.-Y., Lin, C.-W., Lin, H.-H., Yao, M., Tang, J.-L., Wu, S.-J., Chen, Y.-C., Lu, H.-Y., Hou, H.-A., Chen, C.-Y., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2063-7 · Cited by 62 · see citing works

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607 · see citing works

High expression of cereblon (<i><scp>CRBN</scp></i>) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone

Heintel, D., Rocci, A., Ludwig, H., Bolomsky, A., Caltagirone, S., Schreder, M., Pfeifer, S., Gisslinger, H., Zojer, N., Jäger, U., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12338 · Cited by 128 · see citing works

Cereblon expression in multiple myeloma: not ready for prime time

Lodé, L., Amiot, M., Maïga, S., Touzeau, C., Ménard, A., Magrangeas, F., Minvielle, S., Pellat‐Deceunynck, C., Béné, M. C., & Moreau, P. (2013) · British Journal of Haematology · doi:10.1111/bjh.12478 · Cited by 20 · see citing works